Skip to main content
Premium Trial:

Request an Annual Quote

Frost & Sullivan Forecast Growth, Changes in Reagent Market

NEW YORK, Feb. 20-Revenues for biomedical research reagents in the United States climbed to $981 million last year and may be worth more than $2 billion by 2007, according to a new report from Frost & Sullivan.

 

The report, "U.S. Research Biochemical Markets," tracks the growth of demand for biochemicals like antibodies and enzymes that are used in immunochemistry, cell culture work and genomic research.

 

The market is strong, but the report warns that it is also changing rapidly. Patent expirations are transforming the business. As patents expire, reagents become more widely available as products. Competition intensifies, prices drop, and profit margins can dwindle.

 

As a result, biochemical makers will face pressure unless they find ways to protect their patents and intellectual property.

 

One strategy: to use old products in new combination technologies.

 

Another strategy: strengthening brand image. "Market leaders in research biochemicals industry have very well-respected, long standing brand names," said Frost & Sullivan analyst Brad Peters in a statement released by the company.

 

The consulting company also recognized six companies in the biochemical industry with "Marketing Engineering Awards": Applied Biosystems, Invitrogen, New England Biolabs, NuGEN Technologies, Promega, and Roche Applied Science.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.